Cargando…

Stratification of Hepatocellular Carcinoma Risk Following HCV Eradication or HBV Control

Hepatocellular carcinoma (HCC) incidence has dramatically decreased in patients infected with HCV and HBV due to the widespread use of highly effective antiviral agents. Nevertheless, a substantial proportion of patients with advanced fibrosis or cirrhosis following HCV clearance of in case of HBV c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nahon, Pierre, Vo Quang, Erwan, Ganne-Carrié, Nathalie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832303/ https://www.ncbi.nlm.nih.gov/pubmed/33477752 http://dx.doi.org/10.3390/jcm10020353

Ejemplares similares

Management of patients with pre-therapeutic advanced liver fibrosis following HCV eradication
por: Nahon, Pierre, et al.
Publicado: (2019)

Determination of candidate metabolite biomarkers associated with recurrence of HCV-related hepatocellular carcinoma
por: Liu, Zhicheng, et al.
Publicado: (2017)

HCC risk prediction using biomarkers in non-cirrhotic patients following HCV eradication: Reassuring the patient or the doctor?
por: Costentin, Charlotte E., et al.
Publicado: (2021)

BRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease
por: Oussalah, Abderrahim, et al.
Publicado: (2016)

Impact of cirrhosis aetiology on incidence and prognosis of hepatocellular carcinoma diagnosed during surveillance
por: Ganne-Carrié, Nathalie, et al.
Publicado: (2021)

Hepatitis B Virus (HBV) Reactivation Following Pharmacological Eradication of Hepatitis C Virus (HCV)
por: Pisaturo, Mariantonietta, et al.
Publicado: (2019)

Seroprevalence of HBV and HCV in primary hepatocellular carcinoma patients in Zimbabwe
por: Chin'ombe, Nyasha, et al.
Publicado: (2009)

Sulfatase 2 Along with Syndecan 1 and Glypican 3 Serum Levels are Associated with a Prognostic Value in Patients with Alcoholic Cirrhosis-Related Advanced Hepatocellular Carcinoma
por: Mouhoubi, Nesrine, et al.
Publicado: (2022)

Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease
por: Semmler, Georg, et al.
Publicado: (2021)

Risk of hepatocellular carcinoma after HCV eradication: Determining the role of portal hypertension by measuring spleen stiffness
por: Dajti, Elton, et al.
Publicado: (2021)

Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis
por: Nahon, Pierre, et al.
Publicado: (2021)

Impact of HCV viremia on HBV biomarkers in patients coinfected with HBV and HCV
por: Tseng, Chih-Wei, et al.
Publicado: (2022)

Differential Effect of HCV Eradication and Fibrosis Grade on Hepatocellular Carcinoma and All-cause Mortality
por: Lee, Yun Bin, et al.
Publicado: (2018)

HBV and HCV Therapy
por: Lampertico, Pietro, et al.
Publicado: (2009)

Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV Eradication with Direct-Acting Antivirals
por: Vernuccio, Federica, et al.
Publicado: (2022)

APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation
por: Kanda, Tatsuo, et al.
Publicado: (2019)

Epidemiology of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Related Hepatocellular Carcinoma
por: Petruzziello, Arnolfo
Publicado: (2018)

A comprehensive genome-wide profiling comparison between HBV and HCV infected hepatocellular carcinoma
por: Sun, Suofeng, et al.
Publicado: (2019)

Senescence in HBV-, HCV- and NAFLD- Mediated Hepatocellular Carcinoma and Senotherapeutics: Current Evidence and Future Perspective
por: Giannakoulis, Vassilis G., et al.
Publicado: (2021)

Differential expression of long noncoding RNA in hepatocellular carcinoma on top of chronic HCV and HBV infections
por: Sabry, Hany S., et al.
Publicado: (2021)

Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents
por: Yoo, Hae Won, et al.
Publicado: (2022)

Occult and Overt HBV Co-Infections Independently Predict Postoperative Prognosis in HCV-Associated Hepatocellular Carcinoma
por: Chang, Ming-Ling, et al.
Publicado: (2013)

Molecular Signature and Immune Landscape of HCV-Associated Hepatocellular Carcinoma (HCC): Differences and Similarities with HBV-HCC
por: De Battista, Davide, et al.
Publicado: (2021)

Incidence of hepatocellular carcinoma in a community-based Taiwanese population without chronic HBV/HCV infection
por: Wu, Hui-Chen, et al.
Publicado: (2021)

Imaging and histological features of tumor biopsy sample predict aggressive intrasegmental recurrence of hepatocellular carcinoma after radiofrequency ablation
por: Gigante, Elia, et al.
Publicado: (2022)

The influence of interleukin 28B polymorphisms on the risk of hepatocellular carcinoma among patients with HBV or HCV infection: An updated meta-analysis
por: Qin, Shaoyou, et al.
Publicado: (2019)

Publisher Correction: Differential Effect of HCV Eradication and Fibrosis Grade on Hepatocellular Carcinoma and All-cause Mortality
por: Lee, Yun Bin, et al.
Publicado: (2019)

Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis
por: Abe, Kazumichi, et al.
Publicado: (2020)

Eradication of Hepatitis C Virus (HCV) Improves Survival of Hepatocellular Carcinoma Patients with Active HCV Infection – A Real-World Cohort Study
por: Luo, Yang, et al.
Publicado: (2020)

Mutations in the HBV PreS/S gene related to hepatocellular carcinoma in Vietnamese chronic HBV-infected patients
por: Thi Cam Huong, Nguyen, et al.
Publicado: (2022)

Dynamic of systemic immunity and its impact on tumor recurrence after radiofrequency ablation of hepatocellular carcinoma
por: Rochigneux, Philippe, et al.
Publicado: (2019)

Risk stratification of HBV infection in Asia-Pacific region
por: Kao, Jia-Horng
Publicado: (2014)

The Role of Circulating Free DNA and MicroRNA in Non-Invasive Diagnosis of HBV- and HCV-Related Hepatocellular Carcinoma
por: Pezzuto, Francesca, et al.
Publicado: (2018)

Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study
por: Nagaoki, Yuko, et al.
Publicado: (2021)

Elevated Serum Vinculin in Patients with HBV/HCV-Associated Liver Cirrhosis and Hepatocellular Carcinoma: A Pilot Study
por: Essa, Abdallah, et al.
Publicado: (2023)

HBV and HCV Infection in Children and Adolescents
por: Pokorska-Śpiewak, Maria, et al.
Publicado: (2023)

Update Treatment for HBV Infection and Persistent Risk for Hepatocellular Carcinoma: Prospect for an HBV Cure
por: Yoo, Joseph, et al.
Publicado: (2018)

Highly differential count of circulating and tumor infiltrating immune cells in patients with non-HCV/non-HBV hepatocellular carcinoma
por: Schoenberg, Markus Bo, et al.
Publicado: (2021)

Global immune characterization of HBV/HCV-related hepatocellular carcinoma identifies macrophage and T-cell subsets associated with disease progression
por: Song, Guohe, et al.
Publicado: (2020)

PD-L1 is Fascinating but IDO Needs Attention in Non-HCV and Non-HBV-Associated Hepatocellular Carcinoma Patients
por: Asghar, Kashif, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_iur2lll2sasbb4n4us53dcv2ft